Biogen Inc
NASDAQ:BIIB
Biogen Inc
NASDAQ:BIIB
Price:
220.61 USD
1.43%
Updated:
May 6, 2024
Biogen Inc
Cash from Financing Activities
|
Biogen Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Biogen Inc
NASDAQ:BIIB
|
Cash from Financing Activities
-$246.9m
|
CAGR 3-Years
60%
|
CAGR 5-Years
45%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Biogen Inc's Cash from Financing Activities?
Cash from Financing Activities
-246.9m
USD
-246.9m
USD
Based on the financial report for Mar 31, 2024, Biogen Inc's Cash from Financing Activities amounts to -246.9m USD.
What is Biogen Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
4%
4%
Over the last year, the Cash from Financing Activities growth was 86%. The average annual Cash from Financing Activities growth rates for Biogen Inc have been 60% over the past three years , 45% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet
